

## **ASX ANNOUNCEMENT**

## Simavita secures commitment for \$610k financing by way of Receivable Finance Facility

For Immediate Release: 13 March 2018

**Sydney, Australia** – Simavita Limited (ASX: SVA) ("Simavita" or the "Company") is pleased to confirm the receipt of a first instalment of \$423,793 under a Receivable Finance Facility secured by the Company's 2018 Australian Government's Research and Development Tax Incentive. The total value of the facility for the 12 month period is \$610,443 with the balance payable in instalments up to the end of June 2018.

Simavita has bought forward receipt of these funds in order to rapidly progress its discussions with a number of international manufacturing companies regarding its new transformational platform technology AlertPLUS™.

The R&D Tax Incentive is an Australian Government program developed to assist businesses recover some of the costs of undertaking research and development. Under this program companies receive cash refunds for 43.5% of eligible expenditure on research and development.

For further information, please check our website (www.simavita.com) or contact:

Ms Peta Jurd

E: <u>pjurd@simavita.com</u> T: +61 28405 6361

## **About Simavita**

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the health care industry. Our first products focus on major unmet needs for the assessment and management of incontinence. The annual global economic burden is billions of dollars for incontinence diapers alone and is increasing rapidly.

Simavita operates in Australia, Europe and North America where there is a significant and growing demand for products that deliver real clinical and cost benefits to the health care industry.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. <a href="www.simavita.com">www.simavita.com</a>